Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S A, Van Wart"'
Publikováno v:
Biopharmaceutics & Drug Disposition. 34:215-226
Aim: Clopidogrel is metabolized primarily into an inactive carboxyl metabolite (clopidogrel-IM) or to a lesser extent an active thiol metabolite. A population pharmacokinetic (PK) model was developed using NONMEM® to describe the time course of clop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2195523e50a3abed90d5ce25baa07448
https://doi.org/10.1002/bdd.1839
https://doi.org/10.1002/bdd.1839
Autor:
S. A. Van Wart, Julie A. Passarell, Brenda Cirincione, Paul G. Ambrose, Evelyn J. Ellis-Grosse, Timothy Babinchak, Alison K. Meagher, K. Liolios
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:204-210
Exposure-response analyses were performed to test the microbiological and clinical efficacies of tigecycline in complicated intra-abdominal infections where Escherichia coli and Bacteroides fragilis are the predominant pathogens. Data from evaluable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f706835dd3268294641de2e94ba184
https://doi.org/10.1128/aac.00813-07
https://doi.org/10.1128/aac.00813-07
Autor:
Timothy Babinchak, Brenda Cirincione, S. A. Van Wart, Paul G. Ambrose, Evelyn J. Ellis-Grosse, Alison K. Meagher, Julie A. Passarell, K. Liolios
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:1939-1945
Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a777544b037d8f5564be50b39e199f86
https://doi.org/10.1128/aac.01084-06
https://doi.org/10.1128/aac.01084-06
Autor:
Joel S. Owen, Brenda Cirincione, A. K. Meagher, S. A. Van Wart, Joan M. Korth-Bradley, Elizabeth Ludwig
Publikováno v:
The Journal of Clinical Pharmacology. 47:727-737
Tigecycline, a novel glycylcycline, possesses broad-spectrum antimicrobial activity. A structural population pharmacokinetic model for tigecycline was developed based on data pooled from 5 phase I studies. Intravenous tigecycline was administered as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c9594f97afcf4662bcd8525b466bb6
https://doi.org/10.1177/0091270007300263
https://doi.org/10.1177/0091270007300263
Autor:
Mohamed A. Kamal, Alan Forrest, S. A. Van Wart, Patrick F. Smith, Daniel K. Reynolds, Jeffrey P. Hammel, Paul G. Ambrose, Craig R Rayner, Stephen Toovey, Catharine C. Bulik, Sujata M. Bhavnani
Publikováno v:
Antimicrobial agents and chemotherapy. 57(8)
Given the limited understanding about pharmacokinetic-pharmacodynamic (PK-PD) determinants of oseltamivir efficacy, data from two phase 2 influenza virus inoculation studies were evaluated. Healthy volunteers in studies 1 and 2 were experimentally in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cdb7f0c32b9eea579b74de9c4ff4053
https://pubmed.ncbi.nlm.nih.gov/23669386
https://pubmed.ncbi.nlm.nih.gov/23669386
Publikováno v:
Biopharmaceuticsdrug disposition. 34(4)
Clopidogrel is metabolized primarily into an inactive carboxyl metabolite (clopidogrel-IM) or to a lesser extent an active thiol metabolite. A population pharmacokinetic (PK) model was developed using NONMEM(®) to describe the time course of clopido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18f84555504d61874c92c7c440461877
https://pubmed.ncbi.nlm.nih.gov/23463618
https://pubmed.ncbi.nlm.nih.gov/23463618
Autor:
Alison K. Meagher, Brenda Cirincione, S. A. Van Wart, Joel S. Owen, Joan M. Korth-Bradley, Elizabeth Ludwig
Tigecycline, a first-in-class expanded glycylcycline antimicrobial agent, has demonstrated efficacy in the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal (cIAI) infections. A population pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81036cb41b8932de392fa6a2dfb9fdb
https://europepmc.org/articles/PMC1635236/
https://europepmc.org/articles/PMC1635236/
Autor:
Brenda Cirincione, Susan E. Shoaf, Suresh Mallikaarjun, Thaddeus H. Grasela, S. A. Van Wart, X. Chen, Elizabeth Ludwig
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:P1-P1
AIM TOL is a oral vasopressin (V2) receptor antagonist under development for treatment of CHF and/or HYP. Direct and indirect effect PK/PD models were evaluated to characterize the effect of TOL concentration (Cp) on urine flow rate (UFR) and the inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e03eebf1bfe93356a5249350dd7877df
https://doi.org/10.1016/j.clpt.2005.12.002
https://doi.org/10.1016/j.clpt.2005.12.002